Ginkgo Bioworks Holdings Inc [NYSE: DNA] stock went on an upward path that rose over 2.38% on Friday, amounting to a one-week price increase of more than 6.61%. The company report on January 15, 2024 at 7:00 AM that Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world.
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric’s global network .
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.
Over the last 12 months, DNA stock dropped by -26.70%. The one-year Ginkgo Bioworks Holdings Inc stock forecast points to a potential upside of 57.28. The average equity rating for DNA stock is currently 2.86, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.58 billion, with 1.34 billion shares outstanding and 1.32 billion shares in the current float. Compared to the average trading volume of 21.18M shares, DNA stock reached a trading volume of 14922102 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Ginkgo Bioworks Holdings Inc [DNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNA shares is $3.02 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNA stock is a recommendation set at 2.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Ginkgo Bioworks Holdings Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on November 14, 2023.
The Average True Range (ATR) for Ginkgo Bioworks Holdings Inc is set at 0.10, with the Price to Sales ratio for DNA stock in the period of the last 12 months amounting to 8.18. The Price to Book ratio for the last quarter was 1.91, with the Price to Cash per share for the same quarter was set at 0.53.
DNA Stock Performance Analysis:
Ginkgo Bioworks Holdings Inc [DNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.61. With this latest performance, DNA shares dropped by -27.93% in over the last four-week period, additionally sinking by -42.41% over the last 6 months – not to mention a drop of -26.70% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNA stock in for the last two-week period is set at 42.20, with the RSI for the last a single of trading hit 43.24, and the three-weeks RSI is set at 43.18 for Ginkgo Bioworks Holdings Inc [DNA]. The present Moving Average for the last 50 days of trading for this stock 1.4566, while it was recorded at 1.2580 for the last single week of trading, and 1.6539 for the last 200 days.
Insight into Ginkgo Bioworks Holdings Inc Fundamentals:
Ginkgo Bioworks Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.78 and a Current Ratio set at 6.78.
DNA Stock EPS
With the latest financial reports released by the company, Ginkgo Bioworks Holdings Inc posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.21/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 57.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Ginkgo Bioworks Holdings Inc go to 31.70%.
Ginkgo Bioworks Holdings Inc [DNA] Institutonal Ownership Details
The top three institutional holders of DNA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in DNA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in DNA stock with ownership which is approximately 5.8325%.
